BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 11823980)

  • 1. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
    Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
    Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.
    Radović S; Babić M; Dorić M; Hukić A; Kuskunović S; Hadzismajlović A; Serdarević F
    Bosn J Basic Med Sci; 2007 Aug; 7(3):205-11. PubMed ID: 17848143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
    Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.
    Lai RS; Wang JS; Hsu HK; Chang HC; Lin CH; Lin MH
    Jpn J Clin Oncol; 2002 Oct; 32(10):393-7. PubMed ID: 12451034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
    Harada T; Ogura S; Yamazaki K; Kinoshita I; Itoh T; Isobe H; Yamashiro K; Dosaka-Akita H; Nishimura M
    Cancer Sci; 2003 Apr; 94(4):394-9. PubMed ID: 12824911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
    Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
    Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
    Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
    Saad RS; Liu Y; Han H; Landreneau RJ; Silverman JF
    Mod Pathol; 2004 Oct; 17(10):1235-42. PubMed ID: 15167937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review.
    Haque AK; Adegboyega P; Al-Salameh A; Vrazel DP; Zwischenberger J
    Mod Pathol; 1999 Dec; 12(12):1158-66. PubMed ID: 10619270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
    Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53.
    Huang C; Kohno N; Inufusa H; Kodama K; Taki T; Miyake M
    Am J Pathol; 1999 Sep; 155(3):955-65. PubMed ID: 10487853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.